Grifols SA ADR

Grifols, S.A. is a global healthcare company specializing in the production of plasma-derived medicines, diagnostic solutions, and bio supplies. The company operates across the full plasma value chain — from donor center operations and plasma collection to the fractionation and purification of plasma proteins into therapeutic products, including immunoglobulins, albumin, clotting factors, and other specialty proteins. Grifols also maintains a diagnostics division and a bio supplies segment. The company is dual-listed, with Class A shares trading on the Spanish stock exchanges (SIBE/Continuous Market) and Class B shares listed on NASDAQ via American Depositary Shares (ADSs). Its share structure includes Class A shares (nominal value EUR 0.25) and non-voting Class B shares (nominal value EUR 0.05) that carry a mandatory preferred dividend. The company's subsidiary Biotest AG is consolidated into group results. Grifols has significant business operations in the United States and maintains an international presence across multiple geographies. The CEO is José Ignacio Abia Buenache, a healthcare and life sciences executive recruited from Olympus Corporation in 2024. Updated Jun 18, 2026